Cantor Fitzgerald Comments on IDYA FY2026 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of IDEAYA Biosciences in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will earn ($2.18) per share for the year. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share.

A number of other equities analysts also recently commented on the stock. JPMorgan Chase & Co. upped their target price on shares of IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an “overweight” rating in a research note on Thursday, May 22nd. Stephens reiterated an “overweight” rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $54.27.

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $21.92 on Tuesday. The company has a market capitalization of $1.92 billion, a P/E ratio of -6.64 and a beta of 0.04. The company’s 50-day simple moving average is $18.65 and its two-hundred day simple moving average is $21.22. IDEAYA Biosciences has a one year low of $13.45 and a one year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the firm earned ($0.53) EPS.

Institutional Investors Weigh In On IDEAYA Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in IDEAYA Biosciences during the fourth quarter valued at approximately $47,000. CWM LLC lifted its position in IDEAYA Biosciences by 325.7% during the first quarter. CWM LLC now owns 2,371 shares of the company’s stock valued at $39,000 after acquiring an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in IDEAYA Biosciences by 180.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock valued at $39,000 after acquiring an additional 1,546 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock valued at $72,000 after acquiring an additional 853 shares during the last quarter. Finally, Signaturefd LLC lifted its position in IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock valued at $47,000 after acquiring an additional 2,271 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.